Literature DB >> 2322988

Efficacy of ganglioside treatment in reducing functional alterations induced by vincristine in rabbit peripheral nerves.

F Di Gregorio1, G Favaro, C Panozzo, M G Fiori.   

Abstract

Vincristine (VCR) administration to rabbits resulted in severe electrophysiologic alterations of peripheral nerves. Sciatic nerve conduction velocity, compound action potential (CAP) amplitude, and area under the CAP waveform were all reduced in a dose-dependent fashion. In addition, the pattern of conduction velocity of both motor and sensory fibers was altered and shifted toward slow conduction classes. Simultaneous treatment with gangliosides limited significantly the changes in electrophysiologic parameters induced by VCR. It is suggested that gangliosides be given in the clinical setting as protection for the peripheral nerves against the side effects of antiblastic therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322988     DOI: 10.1007/bf02940290

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  32 in total

1.  Calcium/ganglioside-dependent protein kinase activity in rat brain membrane.

Authors:  J R Goldenring; L C Otis; R K Yu; R J DeLorenzo
Journal:  J Neurochem       Date:  1985-04       Impact factor: 5.372

2.  Impaired axonal transport of acetylcholinesterase in the sciatic nerve of alloxan-diabetic rats: effect of ganglioside treatment.

Authors:  P Marini; M Vitadello; R Bianchi; C Triban; A Gorio
Journal:  Diabetologia       Date:  1986-04       Impact factor: 10.122

3.  Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man.

Authors:  P G Gottschalk; P J Dyck; J M Kiely
Journal:  Neurology       Date:  1968-09       Impact factor: 9.910

4.  Vincristine neuropathy: an electrophysiological and histological study.

Authors:  J G McLeod; R Penny
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-08       Impact factor: 10.154

5.  A new procedure for the extraction, purification and fractionation of brain gangliosides.

Authors:  G Tettamanti; F Bonali; S Marchesini; V Zambotti
Journal:  Biochim Biophys Acta       Date:  1973-01-19

6.  Ganglioside treatment of vincristine-induced neuropathy. An electrophysiologic study.

Authors:  G Favaro; F Di Gregorio; C Panozzo; M G Fiori
Journal:  Toxicology       Date:  1988-05       Impact factor: 4.221

7.  Neurotoxicology of vincristine in the cat. Morphological study.

Authors:  E S Cho; H E Lowndes; B D Goldstein
Journal:  Arch Toxicol       Date:  1983-02       Impact factor: 5.153

8.  Ganglioside GM1 does not initiate, but enhances neurite regeneration of nerve growth factor-dependent sensory neurones.

Authors:  P Doherty; J G Dickson; T P Flanigan; F S Walsh
Journal:  J Neurochem       Date:  1985-04       Impact factor: 5.372

9.  GM1 ganglioside accelerates neurite outgrowth from primary peripheral and central neurons under selected culture conditions.

Authors:  S D Skaper; R Katoh-Semba; S Varon
Journal:  Brain Res       Date:  1985-11       Impact factor: 3.252

10.  Control of axonal caliber by neurofilament transport.

Authors:  P N Hoffman; J W Griffin; D L Price
Journal:  J Cell Biol       Date:  1984-08       Impact factor: 10.539

View more
  3 in total

1.  Vincristine-induced neuropathy in rat: electrophysiological and histological study.

Authors:  Feras M H Ja'afer; Farqad B Hamdan; Faiq H Mohammed
Journal:  Exp Brain Res       Date:  2006-05-31       Impact factor: 1.972

2.  Retardation of rat sciatic nerve regeneration after local application of minute doses of vincristine.

Authors:  G S Ruigt; M H den Brok
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176.

Authors:  Manabu Takagi; Takuya Honmura; Shuuji Watanabe; Reiko Yamaguchi; Masaki Nogawa; Ikumi Nishimura; Fumitaka Katoh; Masato Matsuda; Hiroyoshi Hidaka
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.